publication date: Oct. 23, 2020

In Brief

Wally Curran steps down as director at Emory Winship

Walter J. (Wally) Curran, Jr. said he would step down as executive director of  Winship Cancer Institute of Emory University to serve as the global chief medical officer of GenesisCare, an international group described as “the world’s largest provider of radiation oncology care and a major global provider of other medical services.”

Curran will remain a group chair at NRG Oncology.

“I will be working closely with Winship’s executive leadership team and a small group of internal and external advisors to formulate an interim strategy while a national search is underway,” Jonathan S. Lewin, Emory’s executive vice president for health affairs, wrote in a letter to the faculty and staff. “This advisory group will work with Emory University, Emory Healthcare, and Woodruff Health Sciences leadership to ensure strategies that continue to support the current and future strategic initiatives.”

The text of Curran’s letter distributed to Emory’s faculty and staff on Oct. 22 follows:

Dear Winship,

This past Monday I informed Dr. Jon Lewin of my intent to step down from my role as Winship’s Executive Director effective Jan. 19, 2021. I thanked Jon for all of the support provided to Winship by Emory University, Woodruff Health Sciences Center, and Emory Healthcare over the eleven years I have served in this role.

This support and the extraordinary work of every one of you reading this email has allowed Winship to emerge as one of the elite cancer centers in the nation in cancer care and prevention, research, and education.

I will … Continue reading Wally Curran steps down as director at Emory Winship

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.